| Followers | 37 |
| Posts | 2134 |
| Boards Moderated | 0 |
| Alias Born | 12/20/2010 |
Tuesday, November 13, 2012 7:21:57 PM
Excellent question. Here's what I do in the very order, as I investigate a company.
1. OTCMarkets.com and look at company info to see what the SS is, see if website is listed and current. In this case the SS is super low, and the website is current.
2. OTCMarkets Financials page. Look at current Q for the following:
a. Revenue. In this case BMRA shows $1.7 million Gross sales, with a cost of just over 960k, for a gross profit of $700k. Bottom line profit of roughly $260k. That shows its a productive, working business.
b. Assets. This can be tricky. In some cases the company can show "mystery" assets, such as name recognition. In the case of BMRA we have slightly less than $5 million in assets including cash on hand of $1.3 million and inventories of $1.8 million. TWO VERY NICE NUMBERS.
c. Share Structure Changes. This is THE most important part of reading financials to me. It indicates what the Outstanding share count was at the date of the financials and what it was the quarter before. In this case we have the exact same share structure 6,952,339 on both 8/31 and 5/31. ZERO additional shares produced. You can go back quarter by quarter to see what dilution has occurred, with BMRA there has been virtually none.
d. Toxic Financing. This is number 2 to me in importance. If you dig thru the financials you'll see Convertible Debentures or other forms of toxic financing in some companies. BMRA has none.
3. 8k filings if the company is SEC fully reporting, Press Releases if not. Has the company followed through with promises that they've made? Or does the company rely on notifying shareholders of what they've DONE not what they INTEND to do. In this case, the company does not make promises and "we're gonna's."
So in a nutshell we have a company that has gross sales of $1.7m for the last quarter, with $260k net profit. Over $5 million in assets, including over $1m in both cash and inventory. Zero toxic funding and no Share Structure changes.
In my very humble opinion you're correct not to trust ANYONE in penny stocks. It's much safer that way. Trust the numbers and your instinct. If it smells funny, you're probably going to get burned.
1. OTCMarkets.com and look at company info to see what the SS is, see if website is listed and current. In this case the SS is super low, and the website is current.
2. OTCMarkets Financials page. Look at current Q for the following:
a. Revenue. In this case BMRA shows $1.7 million Gross sales, with a cost of just over 960k, for a gross profit of $700k. Bottom line profit of roughly $260k. That shows its a productive, working business.
b. Assets. This can be tricky. In some cases the company can show "mystery" assets, such as name recognition. In the case of BMRA we have slightly less than $5 million in assets including cash on hand of $1.3 million and inventories of $1.8 million. TWO VERY NICE NUMBERS.
c. Share Structure Changes. This is THE most important part of reading financials to me. It indicates what the Outstanding share count was at the date of the financials and what it was the quarter before. In this case we have the exact same share structure 6,952,339 on both 8/31 and 5/31. ZERO additional shares produced. You can go back quarter by quarter to see what dilution has occurred, with BMRA there has been virtually none.
d. Toxic Financing. This is number 2 to me in importance. If you dig thru the financials you'll see Convertible Debentures or other forms of toxic financing in some companies. BMRA has none.
3. 8k filings if the company is SEC fully reporting, Press Releases if not. Has the company followed through with promises that they've made? Or does the company rely on notifying shareholders of what they've DONE not what they INTEND to do. In this case, the company does not make promises and "we're gonna's."
So in a nutshell we have a company that has gross sales of $1.7m for the last quarter, with $260k net profit. Over $5 million in assets, including over $1m in both cash and inventory. Zero toxic funding and no Share Structure changes.
In my very humble opinion you're correct not to trust ANYONE in penny stocks. It's much safer that way. Trust the numbers and your instinct. If it smells funny, you're probably going to get burned.
Scratch off the broken skin, tear into my heart and make me do it again yeah..
Recent BMRA News
- Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026 • GlobeNewswire Inc. • 04/29/2026 12:19:00 PM
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway • GlobeNewswire Inc. • 04/16/2026 12:19:00 PM
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs • GlobeNewswire Inc. • 04/14/2026 12:19:00 PM
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 04/13/2026 10:57:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 09:15:20 PM
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe • GlobeNewswire Inc. • 03/18/2026 12:19:00 PM
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain • GlobeNewswire Inc. • 03/05/2026 01:19:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2026 10:15:26 PM
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy • GlobeNewswire Inc. • 02/26/2026 01:19:00 PM
- Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution • GlobeNewswire Inc. • 02/18/2026 01:19:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:40:25 PM
- Biomerica Reports Second Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 01/14/2026 10:17:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/14/2026 10:15:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/31/2025 10:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/31/2025 10:10:03 PM
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test • GlobeNewswire Inc. • 12/23/2025 01:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 01:19:33 PM
- Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio • GlobeNewswire Inc. • 12/11/2025 01:08:00 PM
- Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS • GlobeNewswire Inc. • 11/25/2025 01:19:00 PM
- Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand • GlobeNewswire Inc. • 11/06/2025 01:19:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/23/2025 08:15:04 PM
- Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S. • GlobeNewswire Inc. • 10/16/2025 12:19:00 PM
- Biomerica Reports First Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 10/15/2025 01:27:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/14/2025 09:11:06 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/09/2025 09:15:26 PM
